Potentiation of the defective monocyte chemotaxis in Hodgkin's disease by in vitro tuftsin treatment.
In vitro pre-incubation of monocytes derived from patients with Hodgkin's disease with tuftsin (50 micrograms/ml) significantly restored the deficient chemotactic responsiveness of these cells to the complement-derived factor C5a, as demonstrated by a monocyte migration assay based on the Boyden technique. Potentiation of the chemotactic responsiveness of monocytes was most significant after elective splenectomy. The results indicate that the specific receptors required for tuftsin activities may be available on the monocyte membranes in Hodgkin's disease. Since tuftsin is a natural, non-immunogenic tetrapeptide that can also be produced synthetically, it may provide a new therapeutic approach in Hodgkin's disease to at least partial restoration of the defective cellular immunity.
D000328:Adult; D000368:Aged; D002634:Chemotaxis, Leukocyte / Q000187:drug effects; D005260:Female; D006689:Hodgkin Disease / Q000276:immunology*; D006801:Humans; D007128:Immunoglobulin Fragments / Q000494:pharmacology*; D008297:Male; D008875:Middle Aged; D009504:Neutrophils / Q000187:drug effects / Q000276:immunology*; D012016:Reference Values; D013156:Splenectomy; D014405:Tuftsin / Q000494:pharmacology*
D007128:Immunoglobulin Fragments; D014405:Tuftsin